First wave of AstraZeneca's CNS R&D group gets the ax
AstraZeneca isn't wasting any time in pushing ahead with draconian cuts to its neuroscience work in its big R&D hub south of Stockholm. The first 50 scientists have already been shown the door, according to local news reports, part of the first wave of 400 job cuts as AstraZeneca ($AZN) slashes a total of 1,100 positions at the research complex.
http://www.fiercebiotech.com/story/first-wave-astrazenecas-cns-rd-group-gets-ax/2012-05-15?
No comments:
Post a Comment